Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences ranexa (ranolazine — chronic angina, legacy breakout) — Rest of World sales ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary
Latest, Q4 2021
0
Period ended Dec 31, 2021
Change on a year earlier
–
0 in Q4 2020
History
20 quarters
Since Q1 2017
Sources
14
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Gilead Sciences Ranexa (ranolazine — chronic angina, legacy breakout) — Rest of World sales ($M) ($M), quarterly Q1 2017–Q4 2021 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/other_ranexa_row
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.